Skip to main content
SpringerLink
Log in

Next-generation sequencing small price in aNSCLC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Yu TM, et al. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer. Value in Health : 8 Jun 2018. Available from: URL: https://doi.org/10.1016/j.jval.2018.04.1372.

  2. Steuten LMG, et al. Cost-effectiveness of multi-gene panel sequencing (MGPS) for advanced non-small cell lung cancer (aNSCLC) patients. 54th Annual Meeting of the American Society of Clinical Oncology : abstr. 6513, 1 Jun 2018. Available from: URL: http://abstracts.asco.org/214/AbstView_214_224835.html.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Next-generation sequencing small price in aNSCLC. PharmacoEcon Outcomes News 806, 17 (2018). https://doi.org/10.1007/s40274-018-5060-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5060-6

Search

Navigation